Ahn-Gook Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Ahn-Gook Pharmaceutical has a total shareholder equity of ₩156.6B and total debt of ₩77.3B, which brings its debt-to-equity ratio to 49.4%. Its total assets and total liabilities are ₩304.2B and ₩147.6B respectively. Ahn-Gook Pharmaceutical's EBIT is ₩4.4B making its interest coverage ratio 17.9. It has cash and short-term investments of ₩19.2B.
Key information
49.4%
Debt to equity ratio
₩77.30b
Debt
| Interest coverage ratio | 17.9x |
| Cash | ₩19.17b |
| Equity | ₩156.56b |
| Total liabilities | ₩147.61b |
| Total assets | ₩304.17b |
Recent financial health updates
Recent updates
Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right Now
Aug 13
Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?
Apr 02Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year
Mar 07Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?
Feb 14Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?
Jan 19Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend
Dec 24A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
Dec 10Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend
Nov 18
Financial Position Analysis
Short Term Liabilities: A001540's short term assets (₩131.5B) exceed its short term liabilities (₩89.1B).
Long Term Liabilities: A001540's short term assets (₩131.5B) exceed its long term liabilities (₩58.5B).
Debt to Equity History and Analysis
Debt Level: A001540's net debt to equity ratio (37.1%) is considered satisfactory.
Reducing Debt: A001540's debt to equity ratio has increased from 13.7% to 49.4% over the past 5 years.
Debt Coverage: A001540's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A001540's interest payments on its debt are well covered by EBIT (17.9x coverage).